Skip to main content
OpenTrials
Completed

NCT Number: NCT05313100

Sugammadex and Smoker's Neuromuscular Block

We compared the durations of antagonizing and of the severity of effect of sugammadex used in antagonizing the rocuronium in smoker and non-smoker total 40 patients with using Train of Four(TOF) neuromuscular monitorization.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

About this study

40 patients from American Society of Anesthesiologist (ASA) I- II class, being smokers for at least 10 years or non-smokers, who will undergo elective surgery were included in this randomized prospective study. Patients underwent routine monitoring and neuromuscular monitoring. Propofol 2 mg/kg and intravenous fentanyl 1 mcg/kg were applied at induction. After the loss of eyelash reflex, intravenous rocuronium 0,6 mg/kg was administered. The patient was intubated at a Train of Four count of 2. Anesthesia was continued with 50% O2 + 50% air and sevoflurane 2 % . Rocuronium 0,15 mg/kg was administered when TOF (Train of Four) counter reached 2 during the operation. Sugammadex 2 mg/kg was administered at the end of the operation. The time to reach Train of Four values of 0,7-0,8-0,9 were recorded.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Elective surgery,
  • 1-2 according to the ASA ( American Society of Anesthesiologist ) physical status classification.
  • Patients who have smoked at least 10 packs or have been smoking for 10 years and currently smoking
  • Or never smoked patients

Exclusion criteria

  • neuromuscular diseases
  • radiotherapy and/or chemotherapy anamnesis,
  • liver and/or renal disease,
  • electrolyte balance,
  • history of drug use which affects neuromuscular transmission,
  • Body Mass Index (BMI) of more than 27,
  • use alcohol

Treatment and study plan

Sugammadex

Drug

At the end of the operation, at least 15 minutes after the last dose of rocuronium, sugammadex 2 mg / kg was administered both of groups

Other names: bridion

Primary outcomes

  1. Neuromuscular block recovery time

    Time frame: six months

    Time to reach TOF %90 measurement after given neuromuscular blocker reverse agent

Sponsors and collaborators

Lead sponsor

Duzce University

Other

Registry information

Official study title

The Evaluation of the Effects of the Use of Rocuronium and Sugammadex on Neuromuscular Block in Smoker

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Apr 6, 2022
Registry last updated
Apr 18, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.